Izotropic Technology Founder Appointed Editor-In-Chief of Medical Physics Journal
VANCOUVER, BC - TheNewswire – December 31, 2020 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE:IZO) (CNSX:IZO.CN) US (OTC:IZOZF) (FSE:1R3) is pleased to highlight the appointment of Director and Principal Founder of Breast CT Technology, Dr. John M. Boone, as the Editor-In-Chief of the American Association of Physicists in Medicine’s (AAPM) flagship medical journal ‘Medical Physics,’ effective January 1, 2021.
The Company congratulates Dr. Boone on this appointment, as he continues to be recognized as a key thought leader in the field of medical physics.
Dr. Boone has been active in journal editorial issues for over 3 decades and has previously served in leadership positions with the AAPM, an organization of over 9000 scientists, including Chair of Science Council for 6 years, president (2015), and Chair of the Board (2016).
Izotropic Corporation: Izotropic Reports High Degree of Confidence After Pre-Submission Meeting with FDA
Izotropic Corporation (CSE:
Izotropic or the
Company ) announces it has received the finalized meeting minutes from the U.S. Food and Drug Administration (FDA) in connection with the Company s recent pre-submission meeting and the market approval process for its commercial Breast CT Imaging System.
Dr. John McGraw, Executive Vice-President of Commercial Operations, stated, I am pleased to report that the meeting with the FDA was very beneficial for Izotropic and the comments received have validated our clinical study plan and development efforts to date. The initial indication for use for breast CT as a diagnostic device has been confirmed, and we have come away from the meeting with a high degree of confidence in our U.S. market approval plan moving forward.
Izotropic” or the “
Company“) announces it has received the finalized meeting minutes from the U.S. Food and Drug Administration (FDA) in connection with the Company’s recent pre-submission meeting and the market approval process for its commercial Breast CT Imaging System.
Dr. John McGraw, Executive Vice-President of Commercial Operations, stated, “I am pleased to report that the meeting with the FDA was very beneficial for Izotropic and the comments received have validated our clinical study plan and development efforts to date. The initial indication for use for breast CT as a diagnostic device has been confirmed, and we have come away from the meeting with a high degree of confidence in our U.S. market approval plan moving forward.”
Izotropic Reports High Degree of Confidence after Pre-Submission Meeting with FDA
VANCOUVER, BC - TheNewswire - December 15, 2020 - Izotropic Corporation ( Izotropic or the Company ) (CSE:IZO) (CNSX:IZO.CN) (OTC:IZOZF) (FSE:1R3) announces it has received the finalized meeting minutes from the U.S. Food and Drug Administration (FDA) in connection with the Company s recent pre-submission meeting and the market approval process for its commercial Breast CT Imaging System.
Dr. John McGraw, Executive Vice-President of Commercial Operations, stated, I am pleased to report that the meeting with the FDA was very beneficial for Izotropic and the comments received have validated our clinical study plan and development efforts to date. The initial indication for use for breast CT as a diagnostic device has been confirmed, and we have come away from the meeting with a high degree of confidence in our U.S. market approval plan moving forward.